Firebrick Pharma Ltd: June 2024 Quarterly Activity Report & Appendix 4C
Firebrick Pharma Ltd: Change of Director's Interest Notice - Peter Molloy
Firebrick Pharma Ltd: Nasodine Phase 1 Paper Published
Firebrick Pharma Ltd: Firebrick Launches Nasodine in Singapore
Firebrick Pharma Ltd: Nasodine Composition Patent Granted in South Africa
Firebrick Pharma Ltd: Notice of Change in Auditor
Firebrick Pharma Ltd: March 2024 Quarterly Activity Report & Appendix 4C
Firebrick Pharma Ltd: Nasodine Nasal Spray Launch in the USA
Firebrick Pharma Ltd: Nasodine Phase 2 COVID-19 Trial Results Published
Firebrick Pharma Ltd: Nasodine COVID-19 Patent Allowed in US
Firebrick Pharma Ltd: December 2023 Quarterly Activity Report & Appendix 4C
Firebrick Pharma Ltd: Release of Securities from Escrow
Firebrick Pharma Ltd: Firebrick Closes AAT Appeal
Firebrick Pharma Ltd: Nasodine COVID-19 Patent Granted in South Africa
Firebrick Pharma Ltd: Firebrick Investor Update
Firebrick Pharma Ltd: Firebrick Receives $1.81m R&D Tax Incentive
Firebrick Pharma Ltd: September 2023 Quarterly Activity Report & Appendix 4C
Firebrick Pharma Ltd: Update on Nasodine Trial and Forward Plans
Firebrick Pharma Ltd: Notice of AGM and Closing Date for Director Nominations
Firebrick Pharma Ltd: Phase 3 Common Cold Trial Results
No Data